Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Durham, NC, US. The stock last traded at $29.02, up 1.36% on the session, giving a market capitalisation of $100.9M. On trailing twelve-month figures it carries a trailing P/E of -0.71, a net margin of -186.2%. Its beta of 3.13 implies it has historically moved more than the broad market.
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Pelthos Therapeutics Inc. is most often compared with the following Healthcare names: